These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2007-001448-33 A multi-centre, double-blind, randomised, placebo-controlled trial using CD133 enriched bone marrow cells following primary angioplasty for acute myocardial infarction with central core laboratory ana... not-yet-due
Other 2016-001865-99 Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone: a multicentre, open-label, parallel-group, phase II-III, randomised superiori... not-yet-due
Ongoing 2016-004576-22 SAFETY, FEASIBILITY AND COST-ANALYSIS OF UGT1A1 GENOTYPE-GUIDED DOSING OF IRINOTECAN Geïndividualiseerd doseren van irinotecan door middel van genotyperen not-yet-due
Ongoing 2017-000927-29 Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a multice... not-yet-due
Ongoing 2019-002290-63 Bidirectional treatment consisting of repetitive laparoscopic electrostatic pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) and systemic intravenous chemotherapy for isol... not-yet-due
Ongoing 2019-004045-33 PredicTive value of FluoR-18 PSMA-1007 PET/CT and anti-3-[18F] FACBC PET/CT before PLND for lymph nodE staging in primary pRostate cancer not-yet-due
Other 2020-002141-42 Multicentre, open-label, randomised, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locall... not-yet-due
Ongoing 2020-005091-36 Signal TrAnsduction Pathway activity analysis for OVarian cancER treatment. STAPOVER study Signaaltransductie pad activiteit analyse voor de behandeling van eierstokkanker. STAPOVER studie not-yet-due
Ongoing 2022-002134-14 Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases – a phase II study Intraperitoneale irinotecan met gelijktijdig FO... not-yet-due